|
Mar 14
|
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Feb 26
|
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
|
|
Dec 4
|
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
|
|
Nov 28
|
180 Life Sciences Announces Review of Strategic Alternatives
|
|
Aug 10
|
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
|
|
Aug 7
|
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
|